Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Minnesota
Clinical trial register · United States · industry-sponsored

Clinical Trials in Minnesota, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9122 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 07 Oct 2026, 03:16 UTC
9122
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2190
Lead sponsors
across recruiting studies
Top states
California 113 Florida 110 Massachusetts 66 Georgia 63 Illinois 62
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca36 Novartis Pharmaceuticals23 AbbVie19 Eli Lilly and Company18 Bristol-Myers Squibb16 Clear sponsor filter
State
California113 Florida110 Massachusetts66 Georgia63 Illinois62
All 47 states
Target enrolment
to

Trials with a site in Minnesota

23 of 9122 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
NCT07421167Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
DrugsTpo-Ra·Avatrombopag·Romiplostim·Eltrombopag
Novartis Pharmaceuticals
Phase 2
164
Arkansas, Connecticut, Florida, Illinois, Louisiana, Minnesota, Missouri, Montana
2026-08-04
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Arizona, California, Colorado, Florida, Minnesota
2026-06-03
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Colorado, Georgia, Iowa, Minnesota
2026-03-26
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
NCT06868290ANCA Associated Vasculitis (AAV)
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
126
Colorado, Florida, Illinois, Massachusetts, Michigan, Minnesota, North Carolina, Oregon
2025-03-13
Recruiting
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
NCT06531499Metastatic Castration-Resistant Prostate Cancer
DrugLu-PSMA
Novartis Pharmaceuticals
Phase 1
106
California, Minnesota, Missouri, Nebraska
2024-11-11
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896Scleroderma, Diffuse
DrugsRapcabtagene autoleucel·Rituximab
Novartis Pharmaceuticals
Phase 2
96
California, Florida, Illinois, Iowa, Massachusetts, Michigan, Minnesota, Ohio
2024-10-29
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Active, closed
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT06247995Breast Cancer
DrugsGa-NeoB·Lu-NeoB·Capecitabine
Novartis Pharmaceuticals
Phase 1/2
20
California, Minnesota, Texas, Wisconsin
2024-08-14
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Arizona, Minnesota
2024-08-05
Recruiting
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
NCT05646381Aortic Stenosis
DrugPelacarsen
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Active, closed
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
NCT05983198Prostate Cancer
Novartis Pharmaceuticals
Phase 1
33
Minnesota
2023-11-07
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
106
California, Colorado, Florida, Georgia, Massachusetts, Minnesota, Missouri, New Mexico
2023-10-02
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Alabama, California, Colorado, Florida, Illinois, Indiana, Iowa, Minnesota
2023-07-06
Active, closed
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469Myeloid Diseases
Novartis Pharmaceuticals
Phase 1
71
California, Florida, Illinois, Maryland, Massachusetts, Minnesota, New York, Tennessee
2023-05-08
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
90
Michigan, Minnesota, Washington
2022-12-30
Active, closed
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
DrugsAsciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
568
Colorado, Illinois, Minnesota, North Carolina, Ohio, Oregon, Texas, Virginia
2022-11-21
Recruiting
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
NCT04939610Solid Tumor
Drug177Lu-FAP-2286
Novartis Pharmaceuticals
Phase 1/2
222
Alabama, California, Florida, Illinois, Iowa, Michigan, Minnesota, Missouri
2021-07-30
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
California, Colorado, Louisiana, Massachusetts, Minnesota, Nevada, North Carolina, Texas
2021-03-15
Active, closed
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04417621Melanoma
DrugsNaporafenib·Trametinib·Ribociclib
Novartis Pharmaceuticals
Phase 2
134
California, Florida, Massachusetts, Minnesota, New York, Pennsylvania, Texas
2020-10-30
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Arizona, District of Columbia, Florida, Indiana, Maryland, Massachusetts, Minnesota, New York
2019-11-04
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Colorado, Georgia, Iowa, Minnesota, New York
2019-10-03
Active, closed
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
NCT02962414Tuberous Sclerosis Complex
DrugEverolimus
Novartis Pharmaceuticals
Phase 3
206
Arizona, California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, Ohio
2017-08-23
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Arizona, California, Georgia, Illinois, Kansas, Massachusetts, Michigan, Minnesota
2015-11-02
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 October 2026. https://priyalifescience.com/clinical-trials-usa/state/minnesota

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,122 studies in total at the last sync on 07 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 23 of those studies with a site in Minnesota that also match the filters currently applied.

How many clinical trials are recruiting in Minnesota?

10 of the 23 studies on this page are recruiting new participants as of the 07 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Minnesota), 23 studies
PhaseStudiesRecruitingShare
Phase 28334.8%
Phase 38434.8%
Phase 14217.4%
Phase 1/2218.7%
Phase 4104.3%

Most active sponsors

Lead sponsors with the most studies (Minnesota)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals2310
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.